(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4... /PRNewswire-Asia-FirstCall/ -- China Biologic,Pro...logic" or the "Company"),one of the leading plasma...,Republic of China ("PRC"), announced that it has ...e acquisition of a 90% equity interest in,Chongqin...for a total,consideration of RMB 194,400,000 (appr...
...ng in May, buyers of all flex-,fuel vehicles manuf...d,Volkswagen will find extra reading material in t... the owner,s manual, they,ll receive the Ethanol H...vantages of using ethanol instead of,gasoline, pro...ion (UNICA). , The unique partnership, describ...
...derstanding the Fundamental Mechanism of Angiogene...ction of VEGF - A , , Amgen Launches Angiogenesis...gen (Nasdaq: AMGN ) today announced that results...tential new cancer agents will be presented at the...CR) Annual Meeting in Denver between April 18-22, ...
Other Biology Technology:China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5Brazil's top automakers to distribute 2 million copies of the 'Ethanol Handbook' in partnership with the Brazilian Sugarcane Industry Association 2Brazil's top automakers to distribute 2 million copies of the 'Ethanol Handbook' in partnership with the Brazilian Sugarcane Industry Association 3Brazil's top automakers to distribute 2 million copies of the 'Ethanol Handbook' in partnership with the Brazilian Sugarcane Industry Association 4Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 2Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 3Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 4Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 5Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 6Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 7PPase-2A from Promega
Mouse Anti-Salmonella typhimurium Monoclonal Antibody, Unconjugated, Clone 8C11C from ABR-Affinity BioReagents
AgarACE Enzyme from Promega
TNT® T7 Quick Coupled Transcription/Translation System from Promega
Biology Products: